Use of next-generation sequencing to detect LDLR gene copy number variation in familial hypercholesterolemia

Journal of Lipid Research

Jian Wang¹  Henian Cao¹  Robert A. Hegele²  Jacqueline S. Dron²  Michael A. Iacocca³  Adam D. McIntyre³  John F. Robinson⁴ 

[1] Dentistry, Western University, London, Ontario, Canada;Robarts Research Institute, Western University, London, Ontario, Canada;;Departments of Medicine and Biochemistry, Schulich School of Medicine &Robarts Research Institute, Western University, London, Ontario, Canada;

关键词: diagnostic tools;    lipid and lipoprotein metabolism;    molecular biology/genetics;    LDL;    lipoprotein receptors;    coronary heart disease;   

DOI  :  

来源: DOAJ

【 摘 要 】

Familial hypercholesterolemia (FH) is a heritable condition of severely elevated LDL cholesterol, caused predominantly by autosomal codominant mutations in the LDL receptor gene (LDLR). In providing a molecular diagnosis for FH, the current procedure often includes targeted next-generation sequencing (NGS) panels for the detection of small-scale DNA variants, followed by multiplex ligation-dependent probe amplification (MLPA) in LDLR for the detection of whole-exon copy number variants (CNVs). The latter is essential because ∼10% of FH cases are attributed to CNVs in LDLR; accounting for them decreases false negative findings. Here, we determined the potential of replacing MLPA with bioinformatic analysis applied to NGS data, which uses depth-of-coverage analysis as its principal method to identify whole-exon CNV events. In analysis of 388 FH patient samples, there was 100% concordance in LDLR CNV detection between these two methods: 38 reported CNVs identified by MLPA were also successfully detected by our NGS method, while 350 samples negative for CNVs by MLPA were also negative by NGS. This result suggests that MLPA can be removed from the routine diagnostic screening for FH, significantly reducing associated costs, resources, and analysis time, while promoting more widespread assessment of this important class of mutations across diagnostic laboratories.

【 授权许可】

Unknown